Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma

Steven A. Rosenberg, Beverly S. Packard, Paul M. Aebersold, Diane Solomon, Suzanne L. Topalian, Stephen T. Toy, Paul Simon, Michael T. Lotze, James C. Yang, Claudia A. Seipp, Colleen Simpson, Charles Carter, Steven Bock, Douglas Schwartzentruber, John P. Wei, Donald E. White

Research output: Contribution to journalArticlepeer-review

Abstract

Lymphocytes extracted from freshly resected melanomas can be expanded in vitro and can often mediate specific lysis of autologous tumor cells but not allogeneic tumor or autologous normal cells. We treated 20 patients with metastatic melanoma by means of adoptive transfer of these tumor-infiltrating lymphocytes and interleukin-2, after the patients had received a single intravenous dose of cyclophosphamide. Objective regression of the cancer was observed in 9 of 15 patients (60 percent) who had not previously been treated with interleukin-2 and in 2 of 5 patients (40 percent) in whom previous therapy with interleukin-2 had failed. Regression of cancer occurred in the lungs, liver, bone, skin, and subcutaneous sites and lasted from 2 to more than 13 months. Toxic effects of interleukin-2 occurred, although the treatment course was short (five days); these side effects were reversible. It appears that in patients with metastatic melanoma, this experimental treatment regimen can produce higher response rates than those achieved with interleukin-2 administered alone or with lymphokine-activated killer cells. It is too early to determine whether this new form of immunotherapy can improve survival, but further trials seem warranted.

Original languageEnglish (US)
Pages (from-to)1676-1680
Number of pages5
JournalNew England Journal of Medicine
Volume319
Issue number25
DOIs
StatePublished - Dec 22 1988

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma'. Together they form a unique fingerprint.

Cite this